(S)-1-amino-2-(Cbz-amino)-3-methylbutane | 228557-27-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-amino-2-(Cbz-amino)-3-methylbutane
• 英文别名: benzyl N-[(2S)-1-amino-3-methylbutan-2-yl]carbamate
• CAS: 228557-27-5
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: SMWAWLFHPXJTJU-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  对甲苯磺酰氯 、 (S)-1-amino-2-(Cbz-amino)-3-methylbutane 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以51%的产率得到benzyl (S)-(3-methyl-1-((4-methylphenyl)sulfonamido)butan-2-yl)carbamate
  参考文献：
  名称：

  新型氨基酸衍生亚磺酰胺的合成及其作为酮对映选择性转移氢化的配体的评价

  摘要：

  通过相应氨基醛的还原胺化从氨基酸开始，以中等至良好的产率制备了带有立体异构硫原子的新型手性单亚磺酰基二胺。在金属催化的烷基芳基酮的对映选择性转移氢化中评估了它们作为不对称催化配体的潜力。催化剂是由亚磺酰胺 1a-i 和铑和钌的芳烃配合物原位生成的，催化还原导致形成手性醇，其 ee 含量高达 91%。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

  DOI：

  10.1002/ejoc.200800576
• 作为产物：
  描述：

  CBZ-L-缬氨酰胺 在 dimethyl sulfide borane 、 sodium hydroxide 、 水 作用下， 以 甲苯 为溶剂， 反应 0.25h， 生成 (S)-1-amino-2-(Cbz-amino)-3-methylbutane
  参考文献：
  名称：

  [EN] COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE
  [FR] NOUVEAUX COMPOSES EN TANT QU'INHIBITEURS DE LA PROTEASE SERINE NS3 DU VIRUS DE L'HEPATITE C

  摘要：

  公开号：

  WO2005087721A3

文献信息

• Facile Synthesis of Bicyclic Amidines and Imidazolines from 1,2-Diamines
  作者：Qiang Zhu、Yixin Lu

  DOI：10.1021/ol101747n

  日期：2010.9.17

  A facile synthesis of chiral bicyclic amidines and imidazolines from readily available 1,2-diamines has been developed. The reported synthetic strategy relies on an intramolecular cyclization which involves a carboxylic amide derived imidoyl chloride as a key intermediate and aniline serving as a leaving group.

  已经开发了从容易获得的1,2-二胺轻松合成手性双环am和咪唑啉的方法。报道的合成策略依赖于分子内环化，其中涉及由羧酰胺衍生的亚氨酰氯作为关键中间体，而苯胺作为离去基团。
• <i>N</i>-Urethane-Protected Amino Alkyl Isothiocyanates: Synthesis, Isolation, Characterization, and Application to the Synthesis of Thioureidopeptides
  作者：Vommina V. Sureshbabu、Shankar A. Naik、H. P. Hemantha、N. Narendra、Ushati Das、Tayur N. Guru Row

  DOI：10.1021/jo900675s

  日期：2009.8.7

  Synthetically useful N-Fmoc amino-alkyl isothiocyanates have been described, starting from protected amino acids. These compounds have been synthesized in excellent yields by thiocarbonylation of the monoprotected 1,2-diamines with CS2/TEA/p-TsCl, isolated as stable solids, and completely characterized. The procedure has been extended to the synthesis of amino alkyl isothiocyanates from Boc- and Z-protected amino acids as well. The utility of these isothiocyanates for peptidomimetics synthesis has been demonstrated by employing them in the preparation of a series of dithioureidopeptide esters. Boc-Gly-OH and Boc-Phe-OH derived isothiocyanates 9a and 9c have been obtained as single crystals and their structures solved through X-ray diffraction. They belong to the orthorhombic crystal system, and have a single molecule in the asymmetric unit (Z' = 1). 9a crystallizes in the centrosymmetric space group Pbca, while 9c crystallizes in the noncentrosymmetric space group P2(1)2(1)2(1).
• A novel, simple, chemoselective and practical protocol for the reduction of azides using In/NH4Cl
  作者：G.Vidyasagar Reddy、G.Venkat Rao、D.S. Iyengar

  DOI：10.1016/s0040-4039(99)00614-0

  日期：1999.5

  A simple, mild and efficient method for the reduction of azides to amines using In / NH4Cl is described. (C) 1999 Elsevier Science Ltd. All rights reserved.
• Diazepinones as antiviral agents
  申请人：——

  公开号：US20040116410A1

  公开（公告）日：2004-06-17

  The invention is novel compounds of formula (I) which exhibit an improved therapeutic index and improved metabolic stability which are useful in the treatment and/or prevention of herpes viral infections. Novel intermediates useful in the synthesis of the final compounds are also part of the invention.
• Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
  申请人：Venkatraman Srikanth

  公开号：US20070032434A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.